Collectively, the combination of rapamycin and sorafenib presents a new therapeutic option for counteracting the upregulation of PD-L1 expression in sorafenib-resistant HCC cells, leading to a reduction in tumor aggressiveness. This evidence concerns the gene CD274 and neoplasm.